Drug updated on 4/16/2024
| Dosage Form | Tablet (oral; 200 mg, 400 mg) |
| Drug Class | Endothelin and angiotensin II receptor antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.
Summary
- Sparsentan (Filspari) is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.
- Two studies focusing on the safety and effectiveness of Filspari in treating IgAN and Focal Segmental Glomerulosclerosis (FSGS) were analyzed.
- One study addresses a broad population with IgAN, including both adults and children, emphasizing the need for non-immunosuppressive strategies across different age groups.
- Antihypertensive agents such as RAS inhibitors are beneficial in reducing proteinuria with moderate certainty evidence but show little or no difference in rates of kidney failure or remission according to one study.
- In terms of comparative effectiveness, antihypertensive treatments like RAS inhibitors show promise for reducing proteinuria, while other non-immunosuppressive therapies present mixed results, heavily influenced by subgroup characteristics such as those of Japanese patients with IgAN.
- For steroid-resistant FSGS specifically, sparsentan may be considered an important treatment option due to its potential advantage over irbesartan in reducing proteinuria, though more robust evidence is needed before definitive conclusions can be drawn about its superiority.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Filspari (sparsentan) Prescribing Information. | 2023 | Travere Therapeutics, Inc., San Diego, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Non-immunosuppressive treatment for IgA nephropathy. | 2024 | The Cochrane Database of Systematic Reviews |
| Interventions for focal segmental glomerulosclerosis in adults. | 2022 | The Cochrane Database of Systematic Reviews |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Practical considerations for the use of sparsentan in the treatment of patients with IgAN in clinical practice. | 2023 | International Journal of Nephrology and Renovascular Disease |